Amneal Pharmaceuticals FY Conference Summary Company Overview - **Company**: Amneal Pharmaceuticals (NasdaqGS:AMRX) - **Fiscal Year**: 2025 results discussed, with guidance for 2026 provided - **Key Executives**: Chirag Patel (Co-CEO), Joseph Todisco (Finance), Anthony DiMeo (Investor Relations) Key Points from the Conference 1. Fiscal Year 2025 Performance - 2025 was described as an "amazing year" with raised guidance for future performance [5][7] - The Affordable Medicines Group, which includes generics, injectables, and biosimilars, has grown 5% over the last five years and is expected to grow in high single digits moving forward [7][8] 2. Business Segments - **Affordable Medicines Group**: - Comprises generics, injectables, and biosimilars [7] - Generics segment is strong, with 92% of prescriptions filled using generics [21] - New product launches in ophthalmics and transdermal patches are expected to drive growth [23][24] - **Specialty Segment**: - Despite loss of exclusivity (LOE) for Rytary, the specialty segment is expected to remain steady [99] - Crexont has shown remarkable performance, converting 80% of ER patients in its first year [58][66] - **AvKARE**: - Focused on the VA/DoD channel, which is the most profitable [12] - De-emphasizing low-margin distribution business, which generated approximately $350 million in top line but minimal profit [12][13] 3. Product Highlights - **Crexont**: - Expected to generate $300 million to $500 million in revenue, with potential for more than doubling from $63 million in the current year [66][68] - Designed to improve patient adherence and outcomes compared to Rytary [70] - **Brekiya**: - Targeting cluster headache patients with an auto-injector, projected peak sales of $50 million to $100 million [79][81] - **Biosimilars**: - Upcoming launches include denosumab and Xolair, with significant growth anticipated in 2026 and beyond [31][35] - A pipeline of 110 products, with 27 potential launches planned [40] 4. Strategic Initiatives - Focus on vertical integration for biosimilars and enhancing manufacturing capabilities [120] - Partnership with Pfizer through the Metsera deal, allowing access to 18 countries and exclusive rights for certain products [110][112] 5. Financial Outlook - Guidance for 2026 indicates 7%-8% growth, with potential for higher growth if biosimilars are successfully executed [43][47] - Expected margin improvement of 100 basis points in 2026 due to enhanced manufacturing and distribution capabilities [56] 6. Market Position and Future Growth - Amneal aims to become a top five player in the biosimilars market in the U.S. [124] - Continued investment in R&D, with a budget of $180 million to $200 million [120] - Growth opportunities in international markets, particularly in India and through partnerships in Europe [125] 7. Awards and Recognition - Amneal was awarded "Best Company to Work For" by BioSpace, marking a significant achievement for an affordable medicines company [8] Conclusion - Amneal Pharmaceuticals is positioned for continued growth with a strong focus on innovation, product launches, and strategic partnerships. The company is optimistic about its future in the biosimilars market and aims to enhance its profitability through targeted investments and operational efficiencies.

Financial Data and Key Metrics Changes - In Q4 2025, total company revenues grew 11% to a record $814 million, with adjusted EBITDA increasing by 13% and adjusted EPS rising by 75% [18][19] - For the full year 2025, total company revenue reached $3 billion, an 8% increase, with adjusted EBITDA growing 10% to $688 million and adjusted EPS increasing by 43% to $0.83 [21][20] - Operating cash flow for the full year was strong at $340 million, and net leverage was reduced to 3.5 times [18][21] Business Line Data and Key Metrics Changes - The Affordable Medicines segment was flat at $437 million in Q4, while Specialty revenues surged 38% year-over-year to $167 million, driven by strong demand for key brands like CREXONT and RYTARY [19][20] - AvKARE revenues grew 24% to $211 million in Q4, benefiting from strong growth in the government channel [19] - For the full year 2025, Affordable Medicines grew 4%, Specialty grew 19%, and AvKARE grew 12% [21] Market Data and Key Metrics Changes - The Specialty segment's growth was attributed to the successful launch of CREXONT, which captured over 3% market share within a year of launch, with expectations to double market share in 2026 [9][33] - The company anticipates significant growth in the biosimilars market, with plans to have six biosimilars in the U.S. market by 2027 [7][14] Company Strategy and Development Direction - The company aims to become America's number one affordable medicines company, focusing on innovative therapies and expanding access to complex medicines [6][5] - A strategic focus on vertical integration in biosimilars is emphasized, with plans to enhance manufacturing capabilities and develop a strong commercial platform [14][51] - The company plans to launch 20-30 new products each year in the Affordable Medicines segment, prioritizing complex generics and injectables [12][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing a strong foundation and multiple growth drivers, including new branded launches and a robust pipeline of affordable medicines [29][28] - The company expects continued top and bottom line growth in 2026, with revenue growth projected between 1%-4% and adjusted EBITDA growth between 5%-10% [22][26] Other Important Information - The company was recently added to the S&P SmallCap 600 index, enhancing visibility with the investment community [27] - The company is focused on operational excellence, innovation, and a differentiated portfolio to drive consistent growth for investors [10][11] Q&A Session Summary Question: Market response to CREXONT post-phase IV data - Management noted a significant uptake with 80% of IR patients converting to CREXONT, with plans to double market share in 2026 and reach 100,000 patients [33][34] Question: Growth expectations for AvKARE - Management explained that while the distribution business is declining, the government channel remains strong, and gross margins have improved significantly [39][40] Question: Update on Pfizer GLP-1 partnership - The collaboration with Pfizer is progressing well, with no immediate changes expected, and the company retains marketing rights for 18 countries [49][48] Question: Generic Omnipaque opportunity - Management highlighted the complexity of the supply chain and anticipated gradual market entry, with expectations for meaningful revenue contributions starting in 2027 [60][58] Question: XOLAIR market potential - Management expressed excitement about the XOLAIR opportunity, expecting a significant market share due to strong relationships with large buying groups [59][58]

Financial Data and Key Metrics Changes - In Q4 2025, total company revenues grew 11% to a record $814 million, with adjusted EBITDA increasing by 13% and adjusted EPS rising by 75% [18][19] - For the full year 2025, total company revenue reached $3 billion, an 8% increase, with adjusted EBITDA growing 10% to $688 million and adjusted EPS rising 43% to $0.83 [21][20] - Operating cash flow for the full year was strong at $340 million, and net leverage was reduced to 3.5 times [18][21] Business Line Data and Key Metrics Changes - The affordable medicines segment was flat at $437 million in Q4, while specialty revenues surged 38% year-over-year to $167 million, driven by strong demand for key brands [19][20] - AvKARE revenues grew 24% to $211 million, benefiting from strong growth in the government channel [19] - For the full year, affordable medicines grew 4%, specialty grew 19%, and AvKARE grew 12% [21] Market Data and Key Metrics Changes - The specialty segment's growth was attributed to products like CREXONT, Rytary, and the new Brekiya auto-injector [19] - The company expects to launch 20-30 new products each year in the affordable medicines segment, with a focus on complex generics and injectables [11][12] Company Strategy and Development Direction - The company aims to become America's number one affordable medicines company, focusing on innovative therapies and expanding access to complex medicines [6][5] - A strategic focus on vertical integration in biosimilars is emphasized, with plans to build a strong commercial platform and manufacturing capabilities [7][14] - The company is also enhancing operational efficiency through digitization, automation, and AI [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing a strong foundation and multiple growth drivers, including new branded launches and a robust pipeline of affordable medicines [29][28] - The company anticipates continued growth in 2026, with guidance for revenue growth of 1%-4%, adjusted EBITDA growth of 5%-10%, and adjusted EPS growth of 12%-24% [22][23] Other Important Information - The company was recently added to the S&P SmallCap 600 index, enhancing visibility with the investment community [27] - The company is well-positioned to capitalize on the upcoming wave of biologics losing exclusivity, which presents significant long-term growth opportunities [8][14] Q&A Session Summary Question: Update on CREXONT market response and revenue targets for 2026 - Management reported a significant uptake with 80% of IR patients converting to CREXONT, aiming to double market share and reach 100,000 patients in 2026 [33][34] Question: Clarification on AvKARE's growth expectations - Management explained that while the distribution business is declining, the government channel remains strong, and gross margins have improved significantly [39][40] Question: Status of the Pfizer GLP-1 partnership - The collaboration is progressing well, with no immediate changes expected, and the company retains marketing rights for several countries [49][48] Question: Insights on the generic Omnipaque opportunity - Management acknowledged the complexity of the supply chain but expressed optimism about market entry and growth potential [58][60] Question: Discussion on Xolair and market competition - Management highlighted the limited competition expected in the Xolair market and the potential for significant revenue contributions starting in 2027 [59][60]

Financial Data and Key Metrics Changes - Revenue grew 8% in 2025, reaching $3 billion, with adjusted EBITDA increasing by 10% to $688 million and adjusted EPS rising by 43% to $0.83 [4][21][22] - Q4 revenues increased by 11% to a record $814 million, with adjusted EBITDA growing 13% and adjusted EPS soaring 75% [19][20] Business Segment Data and Key Metrics Changes - Affordable Medicines segment revenue was flat at $437 million, while Specialty revenues surged 38% to $167 million, driven by strong demand for key brands [20] - AvKARE revenues grew 24% to $211 million, benefiting from strong growth in the government channel [20] Market Data and Key Metrics Changes - The specialty segment, particularly CREXONT, achieved a market share of over 3% one year post-launch, with expectations to double revenue in 2026 [9][35] - The company anticipates a significant opportunity in biosimilars, with plans to have six products in the U.S. market by 2027 [6][14] Company Strategy and Development Direction - The company aims to become America's number one affordable medicines company, focusing on innovative therapies and expanding access to complex medicines [5] - Strategic growth opportunities include expanding the injectable segment and building a strong commercial platform for biosimilars [6][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing a strong foundation and a robust pipeline of new product launches [4][30] - The company expects continued top and bottom line growth in 2026, with guidance indicating revenue growth of 1%-4% and adjusted EBITDA growth of 5%-10% [24][25] Other Important Information - The company successfully reduced net leverage from 7.4x in 2019 to 3.5x at the end of 2025, and refinanced its debt to lower interest expenses [22][23] - Amneal was added to the S&P SmallCap 600 index, enhancing visibility with the investment community [29] Q&A Session Summary Question: Update on CREXONT market response and revenue targets - Management noted a significant uptake with 80% of IR patients converting to CREXONT, aiming to double market share and reach 100,000 patients in 2026 [35][36] Question: Growth expectations for AvKARE - Management explained that while the distribution business is declining, the government channel remains strong, with gross margins improving significantly [40][41] Question: Status of the Pfizer GLP-1 partnership - The collaboration is progressing well, with no immediate changes expected, and the company retains marketing rights for 18 countries [49] Question: Generic Omnipaque opportunity and competition - Management acknowledged the complexity of the supply chain but expressed confidence in capturing market share, with plans to introduce additional strengths [56][59] Question: Xolair market potential - Management highlighted the limited competition in the Xolair market and expected strong sales through private label partnerships [58][59]

Core Insights - Multiple biotech companies are experiencing significant stock price increases, reaching new 52-week highs due to clinical advancements, regulatory milestones, and strategic funding initiatives [1] Company Summaries Amylyx Pharmaceuticals Inc. (AMLX) - On September 10, 2025, Amylyx reached a new 52-week high of $12.25, a substantial increase from its previous low of $2.47 [2] - The company announced a $175 million underwritten public offering of common stock, consisting of 17.5 million shares priced at $10.00 each, with an option for underwriters to purchase an additional 2.625 million shares [3] - Proceeds from the offering will support the commercial launch of avexitide, currently in Phase 3 trials, and fund ongoing research and development, general corporate purposes, and working capital [3] - Despite discontinuing the ORION program for AMX0035 due to disappointing results, Amylyx continues to advance other candidates, including AMX0035 for Wolfram syndrome and AMX0114 for ALS [4] Amneal Pharmaceuticals Inc. (AMRX) - On September 10, 2025, Amneal's stock reached a new 52-week high of $9.97 during intraday trading, closing at $9.82, reflecting a slight decline of 0.71% from the previous close [4][5] - The stock's performance is supported by the approval of its risperidone extended-release injectable suspension, enhancing its central nervous system portfolio [5] - Amneal is awaiting FDA decisions on biosimilar candidates for denosumab, with potential regulatory approval expected later in 2025, which could significantly boost revenue [6] - The company is also expanding its specialty portfolio with the rollout of Brekiya and the adoption of CREXONT, alongside a collaboration with Metsera to develop GLP-1 therapies [6] argenx SE (ARGX) - On September 10, 2025, argenx reached a new 52-week high of $779.03, closing slightly lower at $762.89, reflecting a modest intraday decline of 0.54% [7] - The increase in share price follows positive topline results from the ADAPT-SERON trial for VYVGART in seronegative generalized myasthenia gravis, which met its primary endpoint [8] - The successful trial positions argenx to pursue FDA label expansion for VYVGART, potentially broadening its market reach and revenue [8][9] - Upcoming milestones include an R&D spotlight webinar on ARGX-119 and expected label expansion decisions for VYVGART-SC in Japan and Canada by year-end [10]

Core Viewpoint - Knight Therapeutics Inc. is advancing its neurology portfolio by submitting a marketing authorization application for CREXONT in Mexico, addressing the high unmet medical need in Parkinson's disease treatment [1][3]. Company Overview - Knight Therapeutics Inc. is a pan-American specialty pharmaceutical company focused on acquiring, in-licensing, and commercializing pharmaceutical products for Canada and Latin America [9]. - The company operates through its Latin American subsidiaries, including United Medical, Biotoscana Farma, and Laboratorio LKM [9]. Product Information - CREXONT is a novel oral formulation of carbidopa/levodopa (CD/LD) designed for the treatment of Parkinson's disease, featuring both immediate-release granules and extended-release beads [2][4]. - The product was developed in collaboration with Amneal Pharmaceuticals, which holds exclusive rights for regulatory approval and commercialization in Canada and Latin America [2]. Clinical Study - CREXONT was evaluated in the RISE-PD clinical study, a 20-week phase 3 trial involving 630 patients, which successfully met its primary and secondary endpoints [5][6]. - The study demonstrated that CREXONT significantly improved daily "Good On" time by 0.53 hours with fewer doses compared to immediate-release CD/LD, with an average dosing frequency of three times per day versus five times per day for IR CD/LD [6]. Market Context - Parkinson's disease is the fastest-growing neurological disorder globally, with approximately 1 million diagnosed patients in the U.S. and an estimated 500,000 affected individuals in Mexico aged 45 to 60 [7][8]. - The average age of diagnosis for Parkinson's disease is 60, and the number of patients is expected to grow significantly as life expectancy increases [8].

Core Insights - Knight Therapeutics Inc. has announced that its New Drug Submission (NDS) for CREXONT has been accepted for review by Health Canada [1] - CREXONT is a novel oral formulation of carbidopa/levodopa (CD/LD) designed for the treatment of Parkinson's disease, with a market potential exceeding $50 million in Canada and $120 million in Brazil [2][3] - The RISE-PD clinical study demonstrated that CREXONT significantly improves "Good On" time with fewer doses compared to immediate-release CD/LD [7] Company Overview - Knight Therapeutics Inc. is a pan-American specialty pharmaceutical company focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [11] - The company has entered into an agreement with Amneal Pharmaceuticals for exclusive rights to seek regulatory approval and commercialize CREXONT in Canada and Latin America [3] Product Details - CREXONT combines immediate-release granules and extended-release beads, allowing for rapid onset and prolonged drug release [4][5] - The product was studied in a 20-week phase 3 clinical trial involving 630 patients, which met its primary and secondary endpoints [6] Market Context - Parkinson's disease is the fastest-growing neurological disorder globally, with over 100,000 diagnosed patients in Canada and an estimated 6,600 new cases annually [9][10] - The controlled release segment of the Parkinson's treatment market in Canada was valued at $15 million for the twelve-month period ending September 2024 [2]